Medicare Panel Finds Little Support For Amyloid PET Imaging Changes
This article was originally published in The Pink Sheet Daily
MEDCAC panel has low-to-intermediate confidence that there is enough evidence to show beta amyloid positron emission tomography imaging of the brain changes health outcomes. The vote does not bode well for the technology’s coverage proposal due in July.
You may also be interested in...
Physicians in study changed their diagnosis of whether a patient had Alzheimer’s in half of cases after receiving data from PET scans using Lilly’s beta amyloid detecting tracer Amyvid. Study findings were not available when Lilly first asked CMS to conduct the coverage analysis.
Former CMS coverage director Louis Jacques talks about the strong future ahead he envisions for the Medicare coverage-with-evidence-development program and new coverage policies that will be implemented for investigational device exemption trials.
Reimbursement Briefs: Pfizer Joins Big Data Group; Part D Protected Classes; Wikipedia Partners With Cochrane Collaboration
Pfizer is among seven organizations joining the Optum Labs research collaborative; CMS Coverage and Analysis Group Director Louis Jacques moving to private sector, more news in brief.